Moderna (MRNA) Names A New COO, Is The Rally Already Priced In?

Moderna (MRNA) has put a fresh spotlight on its operations after appointing veteran executive Juan Andres as Chief Operating Officer, just as it prepares for the potential commercialization of intismeran autogene and expands its oncology pipeline.

Recent moves in Moderna’s share price suggest momentum has been building, with a 1-day share price return of 6.95%, a 30-day share price return of 39.62% and a 90-day share price return of 175.35%. The 1-year total shareholder return is very large at 643.27%, although the 5-year total shareholder return remains down 34.69%.

Scan how Moderna’s momentum and oncology focus compare to other potential breakout opportunities by reviewing the hand-picked 19 high quality undiscovered gems in the same broader universe.

After a surge like Moderna’s, the hard question is whether the real opportunity still lies ahead or if most of it already sits in the rear-view mirror. The valuation section starts to answer that.

Most Popular Narrative: 70% Overvalued

Moderna last closed at $203.21, while the most followed narrative pegs fair value at $119.56 using a 7.5% discount rate, which implies the recent share price rally already bakes in a lot of optimism.

The analysts have a consensus price target of $119.56 for Moderna based on their expectations of its future earnings growth, profit margins and other risk factors. Given the current share price of $172.94, the analyst price target of $119.56 is 44.7% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.

See why 218 investors see Moderna as 70% overvalued.

Result: Fair Value of $119.56 (OVERVALUED)

Still, the current Moderna story could shift quickly if respiratory vaccine demand weakens further or if competitive pressure in COVID and RSV intensifies.

Find out about the key risks to this Moderna narrative.

Next Steps

Sentiment around Moderna is clearly split, which is exactly when your own work matters most. Move quickly, weigh both sides of the story, and review the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Moderna?

If Moderna has your attention, do not stop here. Broaden your watchlist with fresh ideas that match your risk comfort and income goals.

• Target resilient balance sheets and steady fundamentals with a focused list of solid balance sheet and fundamentals (25 results) that filters out weaker financial profiles upfront.
• Hunt for quality at a reasonable price by reviewing a curated 27 high quality undervalued stocks that screens for strong cash flows and supportive balance sheets.
• Prioritize staying power and lower volatility potential by scanning a pre-filtered 31 resilient stocks with low risk scores built around companies with more resilient risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com